112 reports of this reaction
3.1% of all CISATRACURIUM BESYLATE reports
#7 most reported adverse reaction
ANAPHYLACTIC REACTION is the #7 most commonly reported adverse reaction for CISATRACURIUM BESYLATE, manufactured by Fresenius Kabi USA, LLC. There are 112 FDA adverse event reports linking CISATRACURIUM BESYLATE to ANAPHYLACTIC REACTION. This represents approximately 3.1% of all 3,661 adverse event reports for this drug.
Patients taking CISATRACURIUM BESYLATE who experience anaphylactic reaction should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ANAPHYLACTIC REACTION is moderately reported among CISATRACURIUM BESYLATE users, representing a notable but not dominant share of adverse events.
In addition to anaphylactic reaction, the following adverse reactions have been reported for CISATRACURIUM BESYLATE:
The following drugs have also been linked to anaphylactic reaction in FDA adverse event reports:
ANAPHYLACTIC REACTION has been reported as an adverse event in 112 FDA reports for CISATRACURIUM BESYLATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ANAPHYLACTIC REACTION accounts for approximately 3.1% of all adverse event reports for CISATRACURIUM BESYLATE, making it a notable side effect.
If you experience anaphylactic reaction while taking CISATRACURIUM BESYLATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.